Shineco 과거 수익 실적

과거 기준 확인 0/6

Shineco의 수입은 연평균 -18.2%의 비율로 감소해 온 반면, Personal Products 산업은 수입이 연평균 11.7%의 비율로 증가했습니다. 매출은 연평균 54.2%의 비율로 감소해 왔습니다.

주요 정보

-18.2%

수익 성장률

20.5%

EPS 성장률

Personal Products 산업 성장	20.9%
매출 성장률	-54.2%
자기자본 수익률	-90.8%
순이익	-319.4%
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Shineco CEO steps down, new CEO appointed

May 07

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

May 04

수익 및 비용 분석

Shineco 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:SISI 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Jun 24	10	-31	18
31 Mar 24	6	-14	15
31 Dec 23	5	-14	14
30 Sep 23	2	-12	10
30 Jun 23	1	-10	9
31 Mar 23	-2	2	0
31 Dec 22	-1	2	-1
30 Sep 22	-1	2	-1
30 Jun 22	0	-8	6
31 Mar 22	3	-28	23
31 Dec 21	3	-28	23
30 Sep 21	3	-31	24
30 Jun 21	3	-21	17
31 Mar 21	-6	-11	5
31 Dec 20	-3	-13	7
30 Sep 20	4	-7	6
30 Jun 20	10	-7	8
31 Mar 20	26	-5	11
31 Dec 19	30	-2	11
30 Sep 19	31	-2	11
30 Jun 19	31	1	9
31 Mar 19	32	-2	9
31 Dec 18	38	4	6
30 Sep 18	44	7	6
30 Jun 18	44	8	6
31 Mar 18	43	12	4
31 Dec 17	38	9	4
30 Sep 17	35	8	4
30 Jun 17	34	8	3
31 Mar 17	34	8	4
31 Dec 16	33	7	4
30 Sep 16	34	8	4
30 Jun 16	35	8	4
31 Mar 16	35	8	4
31 Dec 15	34	8	4
30 Sep 15	33	7	4
30 Jun 15	33	7	4
31 Mar 15	32	10	3
31 Dec 14	32	8	3
30 Sep 14	30	7	3
30 Jun 14	31	8	2
31 Mar 14	34	7	3

양질의 수익: SISI 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SISI 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SISI 은(는) 수익성이 없으며 지난 5년 동안 연간 18.2% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SISI 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SISI 은(는) 수익성이 없어 지난 해 수익 성장을 Personal Products 업계( 22.2% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SISI 현재 수익성이 없기 때문에 마이너스 자본 수익률( -90.79% )을 갖습니다.

Shineco 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2024 earnings released: US$5.89 loss per share (vs US$5.43 loss in FY 2023)

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Recent updates

Full year 2024 earnings released: US$5.89 loss per share (vs US$5.43 loss in FY 2023)

Shineco, Inc., Annual General Meeting, Oct 21, 2024

Shineco Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Requirement

Shanchun Huang Engages in Discussions with Shineco

Shanchun Huang Engages in Discussions with Shineco

Shineco, Inc. has filed a Follow-on Equity Offering.

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New major risk - Financial position

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

New major risk - Share price stability

New major risk - Financial position

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco, Inc.'S Subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., Receives Marketing Approval from China's Regulatory Body for Its Cardiac 5 Minute Test

New major risk - Market cap size

Shineco, Inc., Annual General Meeting, Jun 28, 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

Shineco, Inc. (NasdaqCM:SISI) signed a letter of intent to acquire 80% stake in Dream Partner Limited for $40 million.

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

High number of new and inexperienced directors

Shineco Receives Deficiency Letter from Nasdaq

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

High number of new and inexperienced directors

Shineco, Inc. Announces Management Changes

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shineco, Inc. Appoints Qiyin Sun as Chief Medical Consultant

High number of new directors

Shineco, Inc. (NasdaqCM:SISI) entered into an agreement to acquire 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd.

Independent Director Harry Edelson has left the company

High number of new directors

Third quarter 2021 earnings released: US$2.36 loss per share (vs US$1.26 loss in 3Q 2020)

Shineco CEO steps down, new CEO appointed

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding terms of proposal to acquire a 51% stake in Mayah Biological Holdings Limited.

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

Shineco, Inc. announced delayed 10-Q filing

New 90-day high: US$4.15

New 90-day high: US$3.82

New 90-day high: US$3.31

First quarter 2021 earnings released: US$0.35 loss per share

Full year earnings released - US$2.25 loss per share

New 90-day low - US$2.71

Shineco, Inc. Announces Management Changes

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding Letter of Intent to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Co., Ltd from Beijing Kanghuayuan Technology Development Co., Ltd and Changzhou Kelinbo Venture Capital Partnership (limited partnership) for $25 million.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기